ArticleHealth science reports2025
Prognostic Value of Combined HBV pgRNA and MELD Score for Mortality in HBV-Related Acute-on-Chronic Liver Failure: A Single-Center Retrospective Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of albumin infusion on 30-day mortality in ICU patients with acute-on-chronic liver failure: a retrospective cohort using MIMIC-IV database.Clinical and experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Rapid prognostic assessment of patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is crucial for optimizing clinical interventions. This study aimed to explore the clinical value of combining Hepatitis B Virus (HBV) pregenomic RNA (pgRNA) with the Model for End-stage Liver Disease (MELD) score predicting the short-term outcomes in HBV-ACLF patients. Methods: This retrospective study enrolled 220 HBV-ACLF patients from Fuqing Hospital in Fujian Province between July 2016 and July 2024. Clinical data collected within 24 h of diagnosis included HBV pgRNA levels, complete blood counts, C-reactive protein, biochemical profiles, coagulation parameters, and MELD scores. Patients were stratified into survival and non-survival groups based on 90-day outcomes. Independent risk factors for mortality were identified through binary logistic regression. Results: During the 90-day follow-up after hospitalization and discharge, 90 patients died, and 130 survived. Nonsurvivors exhibited significantly higher HBV pgRNA levels (6.07 (5.62-6.71) log10pgRNA [IU/mL] vs. 4.12 [3.81-5.06] log10pgRNA [IU/mL], Conclusion: The novel pgRNA-MELD score effectively predicts short-term prognosis in HBV-ACLF patients, offering enhanced clinical utility compared to individual models and guiding timely therapeutic decisions in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.